Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 3, 2026, Syndax Pharmaceuticals, Inc. (SNDX) has a Wall Street consensus price target of $39.33, based on estimates from 22 covering analysts. With the stock currently trading at $21.71, this represents a potential upside of +81.2%. The company has a market capitalization of $1.89B.
Analyst price targets range from a low of $35.00 to a high of $45.00, representing a 25% spread in expectations. The median target of $38.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 20 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SNDX trades at a trailing P/E of -5.8x. Analysts expect EPS to grow +55.7% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SNDX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for SNDX is $39.33, representing 81.2% upside from the current price of $21.71. With 22 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SNDX has a consensus rating of "Buy" based on 22 Wall Street analysts. The rating breakdown is predominantly bullish, with 20 Buy/Strong Buy ratings. The consensus 12-month price target of $39.33 implies 81.2% upside from current levels.
SNDX's current price is $21.71 with a consensus target of $39.33 (81.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $45 for SNDX, while the most conservative target is $35. The consensus of $39.33 represents the median expectation. These targets typically reflect 12-month expectations.
SNDX is well covered by analysts, with 22 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 20 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SNDX stock forecast based on 22 Wall Street analysts shows a consensus price target of $39.33, with estimates ranging from $35 (bear case) to $45 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on SNDX, with a "Buy" consensus rating and $39.33 price target (81.2% upside). 20 of 22 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SNDX analyst price targets range from $35 to $45, a 25% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $39.33 consensus represents the middle ground.